AbbVie Current Ratio 2010-2018 | ABBV

Current and historical current ratio for AbbVie (ABBV) from 2010 to 2018. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. AbbVie current ratio for the three months ending September 30, 2018 was 1.20.
AbbVie Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2018-09-30 $18.47B $15.39B 1.20
2018-06-30 $13.85B $17.22B 0.80
2018-03-31 $20.44B $17.06B 1.20
2017-12-31 $21.22B $16.64B 1.28
2017-09-30 $18.93B $13.03B 1.45
2017-06-30 $16.96B $12.26B 1.38
2017-03-31 $15.55B $8.84B 1.76
2016-12-31 $16.19B $9.78B 1.66
2016-09-30 $16.29B $9.10B 1.79
2016-06-30 $16.79B $9.27B 1.81
2016-03-31 $16.62B $10.66B 1.56
2015-12-31 $16.31B $10.89B 1.50
2015-09-30 $17.91B $8.81B 2.03
2015-06-30 $16.88B $11.26B 1.50
2015-03-31 $15.41B $11.05B 1.39
2014-12-31 $16.08B $11.39B 1.41
2014-09-30 $17.56B $6.64B 2.65
2014-06-30 $17.79B $6.32B 2.82
2014-03-31 $17.33B $6.22B 2.79
2013-12-31 $17.85B $6.88B 2.60
2013-09-30 $16.54B $6.88B 2.41
2013-06-30 $15.66B $6.81B 2.30
2013-03-31 $14.92B $6.77B 2.21
2012-12-31 $15.35B $6.78B 2.27
2012-09-30 $10.93B $5.37B 2.04
2012-06-30 $5.99B $4.84B 1.24
2012-03-31 $6.75B $5.52B 1.22
2011-12-31 $7.35B $5.90B 1.25
2011-09-30 $0.00B $0.00B 0.00
2011-06-30 $0.00B $0.00B 0.00
2011-03-31 $0.00B $0.00B 0.00
2010-12-31 $8.22B $3.76B 2.19
2009-12-31 $0.00B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $137.681B $28.216B
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $391.677B 18.36
Pfizer (PFE) United States $259.009B 14.60
Merck (MRK) United States $205.072B 17.77
Novartis AG (NVS) Switzerland $203.357B 17.38
Eli Lilly (LLY) United States $120.583B 21.20
Sanofi (SNY) France $113.115B 14.01
Novo Nordisk (NVO) Denmark $107.931B 17.53
AstraZeneca (AZN) United Kingdom $103.013B 12.79
GlaxoSmithKline (GSK) United Kingdom $100.041B 13.45
Bristol-Myers Squibb (BMY) United States $88.253B 14.53